Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;26(5):411-417.
doi: 10.1016/j.jiac.2019.12.016. Epub 2020 Feb 18.

Distribution of Legionella species and serogroups in patients with culture-confirmed Legionella pneumonia

Affiliations

Distribution of Legionella species and serogroups in patients with culture-confirmed Legionella pneumonia

Naoyuki Miyashita et al. J Infect Chemother. 2020 May.

Abstract

Legionella species are consistently identified as some of the most common causative agents of severe community-acquired pneumonia (CAP) or nosocomial pneumonia. Although the number of reported Legionella infection cases is gradually increasing in Japan, most cases are diagnosed by a urinary antigen test, which identifies only L. pneumophila serogroup 1. Therefore, assessment of pneumonia-causing Legionella species and serogroups would be important. The Japan Society for Chemotherapy Legionella committee has collected the isolates and clinical information on cases of sporadic community-acquired Legionella pneumonia throughout Japan. Between December 2006 and March 2019, totally 140 sporadic cases were identified, in which L. pneumophila was the most frequently isolated species (90.7%) followed by L. bozemanae (3.6%), L. dumofii (3.6%), L. micdadei (1.4%), and L. longbeachae (0.7%). Among 127 isolates of L. pneumophila, 111 isolates were of serogroup 1, two of serogroup 2, four of serogroup 3, one of serogroup 4, one of serogroup 5, seven of serogroup 6, and one was of serogroup 10. We also assessed in vitro activity of antibiotics against these isolates and showed that quinolones and macrolides have potent anti-Legionella activity. Our study showed that pneumonia-causing Legionella species and serogroup distribution was comparable to that reported in former surveillances. L. pneumophila was the most common etiologic agent in patients with community-acquired Legionella pneumonia, and L. pneumophila serogroup 1 was the predominant serogroup.

Keywords: Community-acquired pneumonia; Legionella pneumophila; Minimum inhibitory concentration (MIC); Serogroups; Species.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Naoyuki Miyashita has received speaker honoraria from Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Pfizer Japan Inc., and Taisho Toyama Pharmaceutical Co., Ltd. Yosuke Aoki has received speaker honoraria from MSD K.K., Shionogi & Co., Ltd. and Pfizer Japan Inc.; and grant support from Shionogi & Co., Ltd. Toshiaki Kikuchi has received grant support from Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Inc., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., and Astellas Pharma Inc. Masafumi Seki has received speaker honoraria from MSD K.K., Pfizer Japan Inc., Taisho Toyama Pharmaceutical Co., Ltd., and Shionogi & Co., Ltd. Kazuhiro Tateda has received speaker honoraria from Pfizer Japan Inc., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd. and Taisho Toyama Pharmaceutical Co., Ltd.; research funding from Otsuka Pharmaceutical Co., Ltd., grant support from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Japan Blood Products Organization, Asahi Kasei Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd., and Toyama Pharmaceutical Co., Ltd.; and donations from Kyorin Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Astellas Pharma Inc., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., and MSD K.K. Nobuko Maki is an employee of Taisho Toyama Pharmaceutical Co., Ltd. Kazuhiko Uchino is an employee of Daiichi Sankyo Co., Ltd. Hiroshi Kiyota has received grant support from Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., and Taiho Pharmaceutical Co., Ltd. Akira Watanabe has received speaker honoraria from MSD K.K., Kobayashi Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., UCB Japan Co. Ltd., AbbVie GK and GlaxoSmithKline K.K.; donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.; payments for manuscript drafting and editing from Iyaku (Medicine and Drug) Journal Co., Ltd.; and grant support from Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Fujifilm Pharma Co., Ltd., and Meiji Seika Pharma Co., Ltd.

Similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources